Table 1. Characteristics of 12 countries included in the study sample.
| Country | Annual number of pregnanciesa | Number of pregnancies with probable active syphilis infectionsa | Neonatal mortality rate (per 1,000 livebirths)b | HIV prevalence (%)c | Antiretroviral therapy coverage for PMTCT (%)d |
|---|---|---|---|---|---|
| Benin | 369,619 | 348 | 33 | 1.1 | 29 |
| Burkina Faso | 766,917 | 6,989 | 29 | 1.0 | 56 |
| DRC | 3,036,898 | 66,617 | 31 | 1.0 | 13 |
| Kenya | 1,622,428 | 11,391 | 25 | 5.9 | 55 |
| Malawi | 724,327 | 15,628 | 27 | 10.3 | 52 |
| Mauritania | 122,246 | 1,820 | 37 | 0.6 | 4 |
| Senegal | 492,601 | 8,377 | 24 | 0.6 | 31 |
| Sierra Leone | 233,917 | 2,260 | 38 | 1.7 | 76 |
| Togo | 201,475 | 1,659 | 24 | 5.2 | 95 |
| Uganda | 1,614,295 | 45,648 | 28 | 2.6 | 53 |
| Tanzania | 2,012,063 | 34,064 | 24 | 7.2 | 73 |
| Zimbabwe | 388,021 | 3,861 | 27 | 15.1 | 89 |
DRC: Democratic Republic of Congo. PMTCT: Prevention of mother to child HIV transmission.
a Data retrieved from supplementary tables provided by Newman et al [27].
b Estimates developed by the UN Inter-agency Group for Child Mortality Estimation [28].
c Refers to the percentage of people ages 15–49 who are infected with HIV. Source: UNAIDS estimates [28].
d Refers to the percentage of pregnant women with HIV who received antiretroviral therapy for PMTCT. Source: UNAIDS estimates [28].